anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Novel, effective influenza vaccination strategies are needed in the elderly who have the highest rate of influenza-related morbidity and mortality. Vaccine efficacy in the elderly is reduced due to immunosenescence and/or, inflamm-aging. This phase IV clinical trial in 240 participants aims to evaluate metabolic predictors of influenza-vaccine specific immune response in a multi-ethnic elderly community cohort in Singapore. Specifically, our novel approach is to evaluate the immunomodulatory roles of vitamin D, diabetes and other metabolic predictors. This study has translational implications (e.g. using vitamin D as an 'adjuvant', evaluating biomarkers of vaccine efficacy) to enhance influenza vaccine immunogenicity in the vulnerable elderly.

Potential benefit: there is a possibility the vaccine may prevent influenza illness or influenza related complication that might have otherwise occurred. This study will contribute to body of knowledge of impact of metabolic factors (vitamin D, DM status) on influenza vaccine immune response, and will be the first study of its kind to be done in an Asian elderly population. Potential risks related to the blood draw and local/systemic side effects from influenza vaccine are anticipated to be minimal.
The present invention relates to a medicine for treating hyperlipemia, which belongs to a medicinal preparation from plant materials; more specifically, the present invention relates to a Chinese medicinal preparation for treating hyperlipemia. The present invention is an oral medicine prepared from the following Chinese medicinal raw materials by weight percentage: 15 to 30% of glossy privet fruit, 10 to 20% of Japanese thistle herb or root, 5 to 20% of white atractylodes rhizome, 5 to 20% of red sage root, 5 to 15% of eucommia bark, 5 to 15% of finger citron, etc. The medicine has the efficiency of strengthening the spleen, tonifying the kidney, regulating qi flow for eliminating phlegm, dispelling stasis and removing toxicity; the medicine has obvious functions of lowering serum total cholesterol (TC), blood serum triglyceride (TG) and low-density lipoprotein (HDL-C) and increasing high-density lipoprotein (HDL-C). The medicine conforms to the blood fat regulating mechanism of the western medicine and is used for preventing and treating hyperlipemia. The medicine has positive curative effect and low toxic and side effect. The medicine is capable of being prepared by a conventional preparation technology and is suitable for large-scale industrial production. The medicine has the advantages of easy acquirement of raw materials, etc.
Podocytes maintain renal filtration integrity when the glomerular filtration barrier (GFB) is integrated. Impairment or attrition of podocytes, leading to compromised GFB permeability, constitutes the primary etiology of proteinuria and is a hallmark pathological feature of diabetic nephropathy (DN). This study centers on Heterogeneous Nuclear Ribonucleoprotein I (HNRNP I), an RNA-binding protein, delineating its role in facilitating DN-induced renal damage by modulating podocyte health. Comparative analyses in renal biopsy specimens from DN patients and high-glucose-challenged podocyte models in vitro revealed a marked downregulation of HNRNP I expression relative to normal renal tissues and podocytes. In vitro assays demonstrated that high-glucose conditions precipitated a significant reduction in podocyte viability and an escalation in markers indicative of apoptosis. Conversely, HNRNP I overexpression was found to restore podocyte viability and attenuate apoptotic indices. IRAK1, a gene encoding a protein integral to inflammatory signaling, was shown to interact with HNRNP I, which promotes IRAK1 degradation. This interaction culminates in suppressing the PI3K/AKT/mTOR signaling pathway, thereby diminishing podocyte apoptosis and mitigating renal damage in DN. This investigation unveils the mechanistic role of HNRNP I in DN for the first time, potentially informing novel therapeutic strategies for DN renal impairment.
Patients receive cisplatin IV over 1 hour and epirubicin hydrochloride IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Patients also receive fluorouracil IV continuously beginning on day 1 or oral capecitabine. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
OBJECTIVE: Anticoagulant therapy is a risk factor for repeated intratumoral hemorrhage and acute enlargement of a vestibular schwannoma (VS) with neurological deficits. Therefore, we describe two cases of patients on oral anticoagulant therapy with intratumoral hemorrhage in which anticoagulant therapy prior to surgical resection was discontinued. We also discuss other similar cases from the literature since this is a rare event.
CASE REPORTS: We described the two cases of intratumoral hemorrhage in acoustic neurinoma and conducted a literature review of similar cases of patients with intratumoral hemorrhage in acoustic neurinoma who were also on oral anticoagulants. Both patients presented with CN-VII palsy prior to surgery; both also fully re-covered after surgery except for hearing loss on the tumor side. Our literature review found 50 cases of VS (reported as vestibular schwannomas in the literature) with intratumoral hemorrhage. From this total, 11 patients used oral anticoagulant therapy with reported poor outcomes and high mortality; 9 of these 11 cases were reported in the past 20 years. The incidence is expected to rise due to increased use of anticoagulant therapy due to onset of atrial fibrillation, atherosclerosis, and thromboembolism from longer human lifespan.
CONCLUSION: Anticoagulant therapy represents a risk factor for intratumoral hemorrhage and acute enlargement of VS tumor mass with neurological deficits.
The invention relates to a polyvinyl pyrrolidone-polyaspartic acid self-assembly nano particle which is the nano particle formed by self-assembly of beta-cyclodextrin end capped polyvinyl pyrrolidone (beta-CD-PVP) and adamantane end capped polyaspartic acid (Ad-p(Asp)) through host-guest interaction of a cyclodextrin end group and an adamantane end group. The polyvinyl pyrrolidone-polyaspartic acid self-assembly nano particle can load a cis-platinum drug to prepare a cis-platinum-loading polyvinyl pyrrolidone-polyaspartic acid self-assembly nano particle. The cis-platinum-loading polyvinyl pyrrolidone-polyaspartic acid self-assembly nano particle is in a spherical shape, grain size is uniform, the size is between 100nm and 200nm, and the dispersity is good. The drug loading capacity of the cis-platinum-loading polyvinyl pyrrolidone-polyaspartic acid self-assembly nano particle is adjustable, and when CDDP/Asp=1, the cis-platinum encapsulation efficiency is 66%, and the drug loading capacity reaches 50%. The cis-platinum-loading polyvinyl pyrrolidone-polyaspartic acid self-assembly nano particle has the slow release effect of the cis-platinum drug. The invention discloses a preparation method of the polyvinyl pyrrolidone-polyaspartic acid self-assembly nano particle.
Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 3 months after the index procedure.
Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it.
A method of curing (or at least treating) HIV, by obtaining small tissue mesenchymal stem cells (stMSC) from adipose tissue of a patient with HIV or from a syngeneic donor or an immuno-compatible donor, wherein said stMSC are i) 4-6 μm in diameter, ii) pluripotent, and iii) have CD11b−, CD34−, CD45−, CD 29, CD 49, Oct 4 and SSEA 4 surface markers when harvested. Preferred sources are autologous adipose tissue. Next those stMSCs are gene edited to provide CCR5− stMSCs and optionally amplified by growth in culture and/or by cell selection for gene edited stMSCs and then re-introducing into the patient. Preferably, the CCR5− stMSCs will re-populate the patient with stem cells that can no longer act as latent HIV reservoirs and can differentiate into immune cells that are HIV resistant. If desired, the patient can be first treated, e.g., by radiation, to destroy the bone marrow cells before the re-introduction. However, this may not be necessary for patient who already has significant destruction of immunity by HIV.
OBJECTIVE: A diagnosis of chronic kidney disease (CKD) may increase the risk for depression. The network perspective focuses on dynamic relationships among individual symptoms, which could advance our understanding of the development of depression during the transition to a diagnosis of CKD. The aim of this study was to use network analysis to examine the longitudinal associations of depressive symptoms from before to after a diagnosis of CKD.
METHOD: The analytic sample included 1,386 participants from the Chinese Health and Retirement Longitudinal Study. Participants were aged 45 years or older and reported a doctor's diagnosis of CKD in any wave of interviews between 2011 and 2018. Depressive symptoms were measured by the 10-item version of the Center for Epidemiological Studies Depression. Cross-lagged panel network analysis was conducted to examine relationships between symptoms at three time points: prediagnosis; onset of diagnosis, and postdiagnosis).
RESULTS: After controlling for other symptoms and covariates, feeling unable to get going and less happiness at prediagnosis were the most predictive of other symptoms at the diagnosis of CKD. Feeling effortful to do everything and depressed mood at the diagnosis of CKD were the most predictive of other symptoms at postdiagnosis.
CONCLUSIONS: Fatigue (i.e., feeling unable to get going, feeling effortful to do everything), less happiness, and depressed mood were central symptoms during the transition to a diagnosis of CKD. These findings highlight the benefits of identifying and managing these central symptoms to reduce the risk of activating other depressive symptoms. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
OsMKK1, a MAPK gene, positively regulates rice Xa21-mediated resistance response and also plays roles in normal growth and development process of rice. The mitogen-activated protein kinase (MAPK) cascade was highly conserved among eukaryotes, which played crucial roles in plant responses to pathogen infection. Bacterial blight is the most devastating bacterial disease. Xa21 confers broad-spectrum resistance to Xanthomonas oryzae pv. Oryzae (Xoo). This study identified that the transcription level of OsMKK1 was up-regulated in resistant response against Xoo, thus overexpression (OsMKK1-OX) and RNA interference (OsMKK1-RNAi) transgenic rice lines under the background of Xa21 was constructed. Compared with recipient control plants 4021, the OsMKK1-OX lines significantly enhanced disease resistance to Xoo, on the contrary, the resistance of OsMKK1-RNAi lines was weakened, demonstrated that OsMKK1 played a positive role in Xa21-mediated disease resistance pathway. A number of pathogenesis-related proteins, including PR1A, PR2 and PR10A showed enhanced expression in OsMKK1-OX lines, supported that these PR genes may be regulated by OsMKK1 to participate in the defense responses. In addition, the agronomic traits of OsMKK1 transgenic plants were affected. Overall, these results revealed the role of OsMKK1 in Xa21-mediated resistance against Xoo and in the normal growth and development process in rice.
PURPOSE: To obtain in high yield a sialo-composite carbohydrate useful as e.g. a medicine by making endoglycosidase act on a composite carbohydrate composed of a sialic acid-contg. sugar chain to directly transfer the sialosugar chain to a sugar chain receptor. CONSTITUTION: Endoglycosidase is made to act on a composite carbohydrate, as a sugar chain donor, composed of a sialic acid-contg. sugar chain to directly transfer the sialosugar chain to a sugar chain receptor without detaching the sialic acid, thus easily affording the objective sialo-composite carbohydrate. Use of a physiologically active peptide having N-acetylglucosamine residue as the sugar chain receptor can synthesize a desired sialo-composite glycopeptide.
The invention discloses a specific Chinese medicinal preparation for treating bronchial asthma. The specific Chinese medicinal preparation is a powder mixture prepared by mixing the following components in parts by dry weight: 1-2 parts of bletilla striata, 1-2 parts of bulbus fritilariae, 1-2 parts of ramulus mori, 1-2 parts of herba scutellariae barbatae and 1-2 parts of agrimony, preferably 1 part of agrimony, 1 part of bulbus fritilariae, 1 part of ramulus mori, 1 part of herba scutellariae barbatae and 1 part of agrimony, wherein the preparation is generally powder and can be a capsule. The preparation is greyish-white powder which takes bitter and cool. The usage and the dosage are as follows: the preparation is taken with warm crystal sugar water before meals thrice a day with 6 grams each time, raw and cold foods, sour and hot foods, fishes, and shrimps and all irritating foods can not be eaten during the day of preparation taking. The preparation follows the principle of 'winter disease being cured in summer'. A patient is suggested to take the preparation after the beginning of summer and before the beginning of autumn under a non-pathogeny condition so that a better healing effect is achieved. Under general conditions, a disease can be cured by taking the preparation for one period of treatment and does not relapse. As proved by practical clinical application to patients, the specific Chinese medicinal preparation has the effective rate of 100 percent on ordinary asthma, bronchial asthma and chronic asthma.
Data were collected between March 2015 and December 2022 on 36,160 unique users in a manner compliant with the Health Insurance Portability and Accountability Act (HIPAA), Personal Health Information Protection Act (PHIPA), and General Data Protection Regulation (GDPR). Of these, 2,786 unique individuals engaged in biometric and self-report data collection. To protect the real-world applicability of the results, users were not given any special instruction or information about the nature or possibility of the current analyses. As consequence, user data varied greatly in terms of engagement and app-use characteristics. To create a single, unified, and consistent dataset that could be leveraged across all intended analyses, data were filtered to only include English-language psychotherapy sessions that contained the required session payloads for algorithm inclusion (see below), and only when all the objective and two subjective measures were completed both before and after each session.
In one aspect, the present invention is directed to a thermally responsive AB diblock copolymer prepared by RAFT polymerization wherein the diblock copolymer comprises poly(N-(3-aminopropyl)methacrylamide hydrochloride)-block-(N-isopropylacrylamide). Nanostructures of the thermally responsive diblock copolymer are formed by molecularly dissolving the diblock copolymer in aqueous solution at room temperature; and increasing the solution temperature to form nanostructures, for example vesicles or micelles. The first RAFT polymerization of an unprotected amino acid based monomer directly in water is also disclosed. The present invention also provides a method of forming shell cross-linked vesicles by adding a RAFT synthesized anionic homopolymer to a solution of the thermally responsive diblock copolymer. A method of forming interpolyelectrolyte complexed micelles or vesicles is also disclosed, the method comprising preparing by sequential aqueous RAFT polymerization a block copolymer comprised of N,N,-dimethyl acrylamide (DMA), N-acryloyl alanine (AAL) and N-isopropyl acrylamide (NIPAM); dissolving the block copolymers into aqueous solution; raising the solution temperature above the lower critical solution temperature of the NIPAM block; allowing the micelle solution to equilibrate; adjusting the pH of the solution to about 5; adding a cationic polymer to the solution; and stirring the solution. The reaction is readily reversed by the addition of a salt solution. In another aspect of the invention a reversible shell cross-linked micelle of a triblock copolymer cross-linked with cystamine is disclosed where a cleaving agent can be added to cleave the micelles. The reaction can be reversed with the addition of tris(2-carboxyethyl)phosphine or dithiothreitol.
PURPOSE:To obtain a dental plaque-dyeing agent not giving unpleasant feeling and irritation during use and capable of simply decolonizing by blending a pigment ingredient which is harmless to living bodies. CONSTITUTION:This dental plaque-dyeing agent is obtained by blending cochineal as a pigment component in an amount of 1-20wt.%, preferably 4-10wt.%, expressed in terms of 100% pigment. The dyeing agent is used in a form of an aqueous solution, a get-like coating agent, a dentifrice, a chewing tablet, a mouth-washing agent, etc. and e.g. when the agent is used in a medical office by a dentist, the agent can be applied as 2-20wt.% aqueous solution to tooth of a patient using a small cotton globe and the agent can also be used as mouth cleaning agent having 1.5-3wt.% cochineal concentration by brushing the tooth using a tooth paste having 5-6wt.% cochineal concentration. After using, the tooth can readily be decolonized by removing the dental plaque by brushing.
Provided is a labeling apparatus that generates a label for labeling a drug container at a healthcare facility. The labeling apparatus includes a code reader that reads a computer-readable code encoding a drug to be stored by the drug container and transmits a signal indicative of the identity of the drug in response to reading the computer-readable code. A non-transitory computer-readable memory stores a drug formulary comprising a plurality of drug entries. A processing component is configured to identify, from the formulary, the identity of the drug corresponding to the computer-readable code and receives a patient identity from a computer-accessible source. A printer is operable to print label content identifying the specific drug onto a label that is to be applied to the drug container. The label content includes the identity of the drug and the patient identity encoded by a label code that is computer-readable.
For Administration by Intravenous Drip:Reconstitute as directed above (For Intravenous Use) prior to diluting with intravenous solution. 

Only those solutions listed above should be used for the intravenous infusion of Nafcillin for Injection, USP. The concentrations of the antibiotic should fall within the range specified. The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of nafcillin is administered before the drug loses its stability in the solution in use.

There is no clinical experience available on the use of this agent in neonates or infants for this route of administration.

This route of administration should be used for relatively short-term therapy (24 to 48 hours) because of the occasional occurrence of thrombophlebitis particularly in elderly patients.

If another agent is used in conjunction with nafcillin therapy, it should not be physically mixedwith nafcillin but should be administered separately. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
A method of imaging. The method includes determining imaging parameters. Further, the method includes acquiring image data from a patient. Additionally, the method includes storing the imaging parameters with the acquired image data. The method also includes retrieving the stored imaging parameters for use in a subsequent examination. Systems and computer-readable medium that afford functionality of the type defined by this method are also contemplated in conjunction with the present technique.
Cases consistent with cytokine release syndrome (CRS) have been reported with rapid infusion rates. CRS is attributed to the release of cytokines by activated monocytes and lymphocytes. Severe acute CRS can cause serious cardiorespiratory events and/or death [see Adverse Reactions (6.2)]. Close compliance with the recommended dosage and infusion time may reduce the incidence and severity of infusion-associated reactions (IARs). Slowing the infusion rate may minimize many of these IARs. 

Reactions at the infusion site may include pain, swelling, and redness of the skin.
Before prescribing medication to suppress or modify cough, it is important that the underlying cause of cough is identified, that modification of cough does not increase the risk of clinical or physiologic complications, and that appropriate therapy for the primary disease is instituted. Check with physician if cough persists after medication has been used for seven days or if high fever, skin rash, or continued headache, or sore throat is present with cough. Caution should be exercised in patients with high blood pressure, heart disease, diabetes mellitus, or thyroid disease. Dextromethorphan should be used with caution in sedated or debilitated patients, and in patients confined to the supine position. Administration of dextromethorphan may be accompanied by histamine release and should be used with caution in atopic children. The antihistamine in Atuss® DS Tannate Suspension may exhibit additive effects with CNS depressants, including alcohol.
The prolonged use of certain sedative drugs such as midazolam, whose metabolism is associated with the production of active metabolites, can lead to difficult management of sedative therapy and ventilatory weaning. The active metabolites, whose production is variable, determine in fact a difficulty in establishing a precision therapy, thus making it necessary to identify new molecules for sedation in pediatric intensive care unit (PICU). Lorazepam (LZ) is a benzodiazepine with an intermediate duration of activity, administered by continuous infusion or intermittent bolus, which has the advantages of higher potency compared to other benzodiazepines, a low cost and a metabolism that does not produce active metabolites. However, the presence of propylene glycol (PG), an excipient present in intravenous LZ formulations, although generally well tolerated, is potentially associated with episodes of tissue toxicity due to accumulation phenomena; this may represent a risk in cases where LZ is administered in high doses. This study, based on pharmacokinetic models obtained from data already available in the scientific literature, aims to define the pharmacokinetic and pharmacodynamic characteristics of LZ for the analgosedation of pediatric patients admitted to intensive care and subjected to mechanical ventilation. Preliminary evaluation of sedative efficacy will be carried out through COMFORT-B scale assessment.